Novo’s IL-6 Ph3 CVOT Posted to CT.gov; Additional Diamyd T1DM Vaccine Analyses
Two cardiometabolic news items have been observed: Novo Nordisk has initiated the Ph3 ziltivekimab CVOT (ZEUS) in 6,200 adults with established ASCVD, CKD, and systemic inflammation; and Diamyd announced the results from two new analyses on the meta-analysis dataset from the four previous trials evaluating the efficacy and safety of the Diamyd vaccine in T1DM. Below, FENIX provides highlights and insights for the respective news items.
About The Author
Matthew has been a thought leader in the high-growth therapeutic areas of diabetes and cardiovascular medicine since 2006, making regular attendance at large and small CV/met scientific meetings and an architect of novel methods for assessing market opportunities. He has over a decade of experience in leading CV/met consulting engagements, is a published author in PM360 and Diabetes Technology & Therapeutics, and has been quoted in The Pink Sheet on anti-thrombotics.
If you receive our email blasts, you already have an account. Log in now
You can read the article’s full content online after purchase.